A gating strategy that utilized the restricted expression of XCR1 in CD8+ cDC1s in the spleen and CD103+ cDC1s in the tumor was adopted to evaluate XCR1 RO and IFN activity in cDC1s following treatment (Figure 4C). The gene discussed is CD8A; the disease is neoplasm.